XmAb13676

Phase 1Biologic

XXencor, Inc.

XmAb13676 is one of 37 biologic programs targeting Idiopathic Inflammatory Myopathies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Inflammatory MyopathiesRecruiting

Rheumatoid ArthritisRecruiting

Idiopathic Inflammatory MyopathiesPhase 1

Recruiting

Rheumatoid ArthritisPhase 1

Recruiting

Competition

Competitive Landscape

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actos

Takeda

Preclinical

2 2

Celexa

AbbVie

Preclinical

1 3

Voltaren

Cataflam

Plaquenil

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 8

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Rheumatoid Arthritis

NCT07230353

Q4 2028

Phase 1Recruiting

Idiopathic Inflammatory Myopathies

NCT07284797

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Completed·XXencor, Inc.·Phase 1·NCT02924402·154 enrolled

Rheumatoid Arthritis1 trial

A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis

Recruiting·XXencor, Inc.·Phase 1·NCT07230353·68 enrolled

Idiopathic Inflammatory Myopathies1 trial

A Phase 1, First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of XmAb657 in Healthy Participants and in Participants With Autoimmune Diseases

Recruiting·XXencor, Inc.·Phase 1·NCT07284797·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for XmAb13676. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XmAb13676 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XmAb13676. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xencor, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: XXencor, Inc.

XmAb13676

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Hematologic Malignancies1 trial

Rheumatoid Arthritis1 trial

Idiopathic Inflammatory Myopathies1 trial

References

Drug Info

Quick Facts

Related News